Pfizer boosts cancer drug roster with $14 billion Medivation deal

(Reuters) - Pfizer Inc , beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Incfor $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi...